[{"trial_metadata": {"citation": "Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 2010;33:1255-1261.", "drug_name": "Exenatide", "phase": "Not specified", "indication": "Type 2 Diabetes", "numeric_trial_duration": 52, "trial_duration": "52 weeks", "safety_population_definition": "All randomized participants who received at least one dose of exenatide in the previously reported phase of this study.", "NCT Number": "NCT00308139", "Sponsor": "Amylin Pharmaceuticals and Eli Lilly & Company", "route of adminstration": "Subcutaneous"}, "baseline_table": [{"variable_label": "Sex", "variable_label_raw": "Sex (%)", "categorical_label": "Demographics", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 68, "percent": 57, "mean": 0, "sd": 0, "raw_value": "68 (57%)"}}, {"variable_label": "Sex", "variable_label_raw": "Sex (%)", "categorical_label": "Demographics", "variable_type": "categorical", "units": "%", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 64, "percent": 53, "mean": 0, "sd": 0, "raw_value": "64 (53%)"}}, {"variable_label": "Age", "variable_label_raw": "Age (y)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 56, "sd": 9, "raw_value": "56 (9)"}}, {"variable_label": "Age", "variable_label_raw": "Age (y)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 55, "sd": 10, "raw_value": "55 (10)"}}, {"variable_label": "Weight", "variable_label_raw": "Weight (kg)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "kg", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 103, "sd": 19, "raw_value": "103 (19)"}}, {"variable_label": "Weight", "variable_label_raw": "Weight (kg)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "kg", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 102, "sd": 20, "raw_value": "102 (20)"}}, {"variable_label": "Body Mass Index", "variable_label_raw": "Body Mass Index (kg/m\u00b2)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "kg/m\u00b2", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 35, "sd": 5, "raw_value": "35 (5)"}}, {"variable_label": "Body Mass Index", "variable_label_raw": "Body Mass Index (kg/m\u00b2)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "kg/m\u00b2", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 35, "sd": 5, "raw_value": "35 (5)"}}, {"variable_label": "A1C", "variable_label_raw": "A1C (%)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "%", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 8.3, "sd": 1.0, "raw_value": "8.3 (1.0)"}}, {"variable_label": "A1C", "variable_label_raw": "A1C (%)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "%", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 8.2, "sd": 0.9, "raw_value": "8.2 (0.9)"}}, {"variable_label": "Fasting Plasma Glucose", "variable_label_raw": "Fasting Plasma Glucose (mg/dL)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "mg/dL", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 172, "sd": 45, "raw_value": "172 (45)"}}, {"variable_label": "Fasting Plasma Glucose", "variable_label_raw": "Fasting Plasma Glucose (mg/dL)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "mg/dL", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 166, "sd": 41, "raw_value": "166 (41)"}}, {"variable_label": "Duration of Diabetes", "variable_label_raw": "Duration of Diabetes (y)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 120, "arm_label": "Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 7, "sd": 6, "raw_value": "7 (6)"}}, {"variable_label": "Duration of Diabetes", "variable_label_raw": "Duration of Diabetes (y)", "categorical_label": "Demographics", "variable_type": "continuous", "units": "years", "arm_result": {"total_n": 121, "arm_label": "Exenatide BID -> Exenatide QW", "arm_role": "treatment", "n": 0, "percent": 0, "mean": 6, "sd": 5, "raw_value": "6(5)"}}], "ae_events": [{"AE_label_raw": "Upper respiratory tract infection", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide QW", "total_n": 128, "arm_role": "treatment", "n_with_event": 16, "percent_with_event": 12.5}}, {"AE_label_raw": "Upper respiratory tract infection", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 16, "percent_with_event": 12.3}}, {"AE_label_raw": "Diarrhea", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide QW", "total_n": 128, "arm_role": "treatment", "n_with_event": 11, "percent_with_event": 8.6}}, {"AE_label_raw": "Diarrhea", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 6.9}}, {"AE_label_raw": "Nausea", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide QW", "total_n": 128, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 7.0}}, {"AE_label_raw": "Nausea", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 10, "percent_with_event": 7.7}}, {"AE_label_raw": "Nasopharyngitis", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide QW", "total_n": 128, "arm_role": "treatment", "n_with_event": 10, "percent_with_event": 7.8}}, {"AE_label_raw": "Sinusitis", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 9, "percent_with_event": 6.9}}, {"AE_label_raw": "Vomiting", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide QW", "total_n": 128, "arm_role": "treatment", "n_with_event": 8, "percent_with_event": 6.3}}, {"AE_label_raw": "Urinary tract infection", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 7, "percent_with_event": 5.4}}, {"AE_label_raw": "Injection site bruising", "event_category": "Treatment-emergent adverse events >5% incidence during open-ended assessment period", "is_any_ae": true, "is_serious_ae": false, "is_fatal": false, "is_ae_leading_to_discontinuation": false, "is_aesi": false, "arm_result": {"arm_label": "Exenatide BID -> Exenatide QW", "total_n": 130, "arm_role": "treatment", "n_with_event": 7, "percent_with_event": 5.4}}]}]